Lilly Asia Ventures
Fei Chen, Ph.D., is a Managing Partner with Lilly Asia Ventures (LAV). Prior to joining LAV in 2009, when LAV was corporate venture arm of Eli Lilly and Co., Fei worked at The Balloch Group, a leading boutique investment banking firm in China, where he provided financial advisory services for local pharmaceutical companies in private placement and cross-border M&A transactions. Fei holds a Ph.D. in molecular genetics and a Bachelor’s degree in biology from Fudan University.
This person is not in the org chart
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.